Facial erythema after the treatment of dupilumab in SLE patient

Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Rec...

Source: Allergy, Asthma and Clinical Immunology - July 3, 2020 Category: Allergy & Immunology Authors: Dong Hyek Jang, Jae In Lee, Joo Yoon Bae, Hye Jung Jung, Mi Yeon Park and Jiyoung Ahn Tags: Case report Source Type: research